ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Building A Flexible, Challenge Resistant, Patient-Centric Clinical Supply Chain

  Flexible solutions, like demand-led supply and direct-to-patient distribution, are helping sponsors address the growing list of challenges presented by today’s increasingly complex studies.

• Building Clinical Supply Agility In A Changing Trial Landscape

  Rising trial complexity demands agile supply built on integrated operations, solid planning, and fast issue resolution. Lean teams gain from partners providing flexibility, control, and global reach.

• Top 5 Dos And Don'ts Of RTSM

  Discover best practices and common pitfalls for sponsors and vendors in RTSM as well as how to optimize your study by leveraging vendor expertise, avoiding delays, and embracing innovation.

• The Patient-Centric Clinical Supply Chain For Cell And Gene Therapies

  This article explores how delivering cell and gene therapies to patients requires new levels of agility, flexibility and innovation in the logistical management of supply. 

• RTSM Reusability: What It Is, Why Most Systems Lack It, And Why It Matters

  Explore why RTSM should be viewed as a system for managing change. Learn how platform-based reusability reduces UAT churn, preserves institutional memory, and stabilizes mid-study amendments.

• How Pharmaceutical Manufacturers Can Take Control Of Their Supply Chain

  In an increasingly competitive and regulated landscape, the right ERP system is no longer optional—it’s essential to reclaim control and drive growth in pharmaceutical manufacturing.

• 3 Study Areas Where Your IRT Vendor Should Do More

  Find out how advanced IRT systems now support diverse trial designs and how the expertise of RTSM vendors is crucial for tailoring solutions to trial needs and providing ongoing support.

• RTSM: Randomization And Cohort Management, IP Inventory Management

  Signant’s SmartSignals® RTSM solution helped an innovative biopharmaceutical company secure an FDA Orphan Drug designation for its cardiomyopathy drug.

• Is Your Clinical Supply Strategy Ready For EU CTR?

  One of the most significant changes in the new EU regulation is Annex VI, which covers changes in the labelling requirements for investigational medical products (IMPs). So, what are the implications of these changes and how will they affect outer immediate packaging? 

• Benefits Of Electronic Labels: Investigational Medicinal Products

  When a new therapeutic drug, medical device, vaccine, or other investigational medicinal product (IMP) is developed, learn why a label must be on its packaging that provides relevant and important information.